Special Issue on“Biomarkers for Diseases”

<正>The journal Genomics ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the winter of 2015)on the topic of‘‘Biomarkers for Diseases’’.As an emerging index,disease biomarkers have demonstrated the potential application in diagnosis and prognosis.The detection of the disease indicators at molecular level,DNA,     

Special Issue on‘‘Biomarkers for Diseases’’

<正>The journal Genomics ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the winter of 2015)on the topic of‘‘Biomarkers for Diseases’’.As an emerging index,disease biomarkers have demonstrated the potential application in diagnosis and prognosis.The detection of the disease indicators at molecular level,DNA,RNA     

Call for Papers Special Issue on “Biomarkers for Diseases”

正The journal Genomics ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in June of 2015)on the topic of"Biomarkers for Diseases".As an emerging index,disease biomarkers have demonstrated the potential application in diagnosis and prognosis.The detection of the disease indicators at molecular level,DNA,RNA,protein or metabolites,could gain highly     

Special Issue on ‘‘Biomarkers for Diseases”

<正>The journal Genomics ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the winter of 2015)on the topic of‘‘Biomarkers for Diseases’’.As an emerging index,disease biomarkers have demonstrated the potential application in diagnosis and prognosis.The detection of the disease indicators at molecular level,DNA,RNA,protein or metabolites,could gain highly sensitive and specific signals that truly reflect     

Identification and characterization of an ancient class of small RNAs enriched in serum associating with active infection

Dear Editor,
The identification of novel serum biomarkers holds great value for diagnosing and monitoring disease conditions due to its convenient and non-invasive nature. Recently, great interests have been shed on serum microRNAs （miRNAs）, which emerge as promising biomarkers for a variety of diseases including cancer and metabolic disorders （Cortez et al., 2011）. Despite the concentrated attention on serum miRNAs, the reports on the existence and diagnostic value of other serum small RNAs remain surprisingly few. In present study,     

Special Issue on ‘‘Biomarkers for Human Diseases and Translational Medicine'

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.Diagnosis upon biomarkers would aid in early and more efficient intervention,while prognostic     

Mesenchymal stem cell-derived small extracellular vesicles in the treatment of human diseases:Progress and prospect

Mesenchymal stem cells(MSCs)are self-renewing,multipotent cells that could differentiate into multiple tissues.MSC-based therapy has become an attractive and promising strategy for treating human diseases through immune regulation and tissue repair.However,accumulating data have indicated that MSC-based therapeutic effects are mainly attributed to the properties of the MSC-sourced secretome,especially small extracellular vesicles(sEVs).sEVs are signaling vehicles in intercellular communication in normal or pathological conditions.sEVs contain natural contents,such as proteins,mRNA,and microRNAs,and transfer these functional contents to adjacent cells or distant cells through the circulatory system.MSC-sEVs have drawn much attention as attractive agents for treating multiple diseases.The properties of MSC-sEVs include stability in circulation,good biocompatibility,and low toxicity and immunogenicity.Moreover,emerging evidence has shown that MSC-sEVs have equal or even better treatment efficacies than MSCs in many kinds of disease.This review summarizes the current research efforts on the use of MSC-sEVs in the treatment of human diseases and the existing challenges in their application from lab to clinical practice that need to be considered.     

Special Issue on “Biomarkers for Human Diseases and Translational Medicine”

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,     

Special Issue on "Biomarkers for Human Diseases and Translational Medicine"

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Special Issue on “Biomarkers for Human Diseases and Translational Medicine”

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the Spring of 2017)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Special Issue on “Biomarkers for Human Diseases and Translational Medicine”

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Epigenetics of human melanoma： promises and challenges

Melanoma is the deadliest form of skin cancer with rising incidence and mortality rates. Although early-stage melanoma is highly curable, advanced-stage melanoma is refractory to treatment. This underscores the importance of prevention and early detection as well as the need to improve treatment and prognostication of human melanoma. Elucidating the underlying mechanisms of the initi- ation and progression of human melanoma can help identify potential targets of intervention for prevention, diagnosis, therapy, and prognosis of this disease. Aberrant DNA methylation and histone modifications are the best-established epigenetic mechanisms of carcinogenesis. The occurrence of epigenetic changes prior to clinical diagnosis of cancer and their reversibility through pharmaco-logic/genetic approaches offer a promising avenue for basic and translational research on human melanoma. Candidate gene（s） or genome-wide aberrant DNA methylation and histone modifications have been observed in human melanoma tumor tissues and cell lines, and correlated to cellular and functional characteristics and/or clinicopathologicai features of this malignancy. The present review summarizes the published researches on aberrant DNA methylation and histone modifications in connection with human melanoma. Representative studies are highlighted to set forth the current state of knowledge, gaps in the knowledgebase, and future directions in these epigenetic fields of research. Examples of epigenetic therapy applied for human melanoma in vitro, and the challenges of its in vivo application for clinical treatment of solid tumors are discussed.     

Special Issue on ‘‘Biomarkers for Human Diseases and Translational Medicine”

正The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Genotoxicity biomarkers in aquatic bioindicators

Pollution of the aquatic environment is an ever-growing problem, as waters are the ultimate sink for the large number of xenobiotics from multiple sources. DNA damaging agents have a significant ecological relevance since they are implicated in many pathological processes and exert effects beyond that of individual being active through following generations. A large number of methods have been applied to evaluate genotoxic damage in different aquatic species. Comet assay, as method for de- tecting DNA alterations, and micronucleus test, as an index of chromosomal damage are the most widely applied and validated methods in field studies. These methods were applied in different vertebrate and invertebrate aquatic species, but only mollusk and fish species have been employed in routine biomonitoring programs. Mussels, due to their widely geographical distribution and the suitability for caging represent the bioindicator of choice in field studies. Mytilus species is the most used marine mussel. The use of fish is limited to specific geographic areas. The present review mainly focuses on the application of comet assay and micronucleus test in mussels. A number of biomonitoring studies in mussels, using comet assay or micronucleus test, revealed exposure to different classes of genotoxic compounds with a good discrimination power. The different evidence from the two as- says, reflects different biological mechanisms for the two genetic endpoints, DNA damage and chromosomal damage, suggesting their combined application in the field. Different endogenous and exogenous factors have been shown to modulate the genotoxic responses in mussels, acting as confounding factors in environmental monitoring. The use of standardized protocol for caging, sampling and genotoxity evaluation is critical in biomonitoring studies. The use of a multimarker approach coupling genotoxicity biomarkers with physiological and biochemical factors allows to have a complete picture of the environmental pollution [Current Zoology 60 （2）： 273-284, 2014].     

Incidence and management of white grub, Schizonycha ruficollis on seedlings of teak （Tectona grandis Linn, f,）

In investigation was conducted annually from 2002 to 2005 between the second week of May and the end of September on the incidence of scarab beetle, Schizonycha ruficollis （Fabricius） in a teak （Tectona grandis L.f.） nursery at Ramdongari, Nagpur, India. The immature stages, that is white grubs of the scarab beetle damaged 14%-52% of teak seedlings in the nursery beds, whereas the adult of the species, that is scarab beetles, were recorded on three new host trees （ Ziziphus xylopyra, Acacia catechu and A. leucophloea） in addition to the reported hosts such as ziziphus （Z. jujuba and Z. mauritiana）. Beetles of the S. ruficollis started emerging from the nursery beds just after the pre-monsoon showers and continued for 10-18 days. While beetle of S. ruficollis defoliated tree hosts available in the surroundings, the immature stages of the beetle caused major damage by feeding on root systerfls of teak seedlings with symptoms of wilting and mortality in forest nursery beds. The result of chemical and biological treatments for the management of grubs of S. ruficollis in nursery beds indicated phorate 10% granular at the rate of 20 g/m^2 and chlorpyriphos 20% emulsifiable concentrate at the rate of 5.0 mL/m^2 to be effective. Grubs of S. ruficollis have not been recorded previously as a major pest of teak （T. grandis）. This is also the first report on occurrence of S. ruficollis adults on tree hosts such as Z. xylopyra, A. catechu and A. leucophloea. White grubs being pests of economic importance and the toughest insects to manage, information given in this paper on incidence, pest status and management of Schizonycha ruficollis is of importance to researchers and forest nursery managers.     

Special Issue on “Biomarkers for Human Diseases and Translational Medicine''

<正>The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the Spring of 2017)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Special Issue on ‘‘Biomarkers for Human Diseases and Translational Medicine'

<正>The journal Genomics,ProteomicsBioinformatics(GPB)is now inviting submissions for a special issue(to be published in the fall of 2016)on the topic of‘‘Biomarkers for Human Diseases and Translational Medicine’’.In the personalized medicine era,disease biomarkers have potential application in diagnosis,prognosis,and guidance for treatment,and are important tools in translational medicine.     

Biomarkers of neurodegenerative disorders： How good are they？

Biomarkers are very important indicators of normal and abnormal biological processes. Specific changes in pathologies,biochemistries and genetics can give us comprehensive information regarding the nature of any particular disease. A good biomarker should be precise and reliable, distinguishable between normal and interested disease, and differentiable between different diseases. It is believed that biomarkers have great potential in predicting chances for diseases, aiding in early diagnosis, and setting standards for the development of new remedies to treat diseases. New technologies have enabled scientists to identify biomarkers of several different neurodegenerative diseases. The followings, for instance,are only a few of the many new biomarkers that have been recently identified: the phosphorylated tau protein and aggregated β-amyloid peptide for Alzheimer‘s disease (AD), α-synuclein contained Lewy bodies and altered dopamine transporter (DAT) imaging for Parkinson‘s disease (PD), SOD mutations for familial amyotrophic lateral sclerosis (ALS), and CAG repeats resulted from Huntington‘s gene mutations in Huntington‘s disease (HD). This article will focus on the most-recent findings of biomarkers belonging to the four mentioned neurodegenerative diseases.